Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - WAC |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - WAC | intrahepatic cholangiocarcinoma | predicted - sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Futibatinib (TAS-120) treatment at a dose of 16mg led to a partial response in 42.1% (8/19) of patients with intrahepatic cholangiocarcinoma harboring FGF or FGFR alterations, including a partial response with a progression-free survival of 6.9 months and a duration of response of 4.2 months in a patient harboring FGFR2-WAC (PMID: 34551969; NCT02052778). | 34551969 | |
FGFR2 - WAC | cholangiocarcinoma | predicted - sensitive | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with Truseltiq (infigratinib) resulted in a partial response in a patient with cholangiocarcinoma harboring an FGFR2-WAC fusion (PMID: 34250419). | 34250419 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|